IMEIK Technology Development Co., Ltd. Investment Quality Review (300896.SZ)

Data timestamp: 2026-07-10 22:04 UTC
Quality score: 79/100 Valuation position: current price/base fair value (FV) 1.29 Final signal: WATCHLIST

Core Conclusion

WATCHLIST is retained because current price/base FV is 1.29, leaving insufficient margin of safety or insufficient primary-evidence support for a buy signal. Current price is 89.45 CNY, with conservative/base FV of 42.95/69.48 CNY. The source memo’s investment judgment is preserved: the signal is controlled by business quality, repeatable FCF, downside protection, primary evidence, and tracking discipline rather than by narrative momentum.

• Business quality: IMEIK Technology Development Co., Ltd. is reviewed as a medical-aesthetics product company. The score is 79/100; the FCF pattern is stable compounding, with median FCF/net income around 0.89.
• Price and valuation: market value is about 270.7 x 100m CNY. Valuation is anchored to normalized FCF and a balance-sheet bridge, not a standalone price target.
• Evidence gate: unverified segment profit, shareholder returns, incentives, financial-asset composition, abnormal items, and related-party or accounting matters remain constraints on any upgrade.

Business Breakdown

The source memo uses the consolidated business line as the valuation anchor because continuous five-year segment profit or gross-margin disclosure was not verified in this run. Segment economics are therefore treated as context, while consolidated revenue, FCF durability, and balance-sheet resilience drive the quality score.

Revenue lens	FY2021	FY2022	FY2023	FY2024	FY2025	Five-year read-through
Consolidated	14.5 x 100m CNY	19.4 x 100m CNY	28.7 x 100m CNY	30.3 x 100m CNY	24.5 x 100m CNY	FY2021-FY2025 revenue CAGR 14.1%; medical-aesthetics product company; valuation uses consolidated FCF as the main anchor when segment profit is undisclosed or not continuously verified

• Value driver: five-year revenue trend, FCF stability, balance-sheet resilience, and the quality of capital allocation set the valuation multiple.
• Disclosure boundary: where segment profit, margin, or management outlook is not quantifiable from primary disclosure, the memo does not infer a better growth rate.

Business Quality Score

The quality score is 79/100. Under the source framework, 80 or above is excellent, 65-79 is good/watch, and below 65 does not meet the preferred business-quality line. The score is not an adjective; it is tied to business model quality, moat, repeatable cash flow, capital return, balance-sheet resilience, growth quality, and management/accounting evidence.

Dimension	Reading
Business model and moat	Reviewed as a medical-aesthetics product company; moat must be visible in revenue durability, pricing, FCF, and primary disclosures.
Repeatable cash flow	The memo uses five complete fiscal years and median FCF/net income of about 0.89 to judge cash conversion quality.
Balance sheet	Cash, current financial assets, non-current financial assets, and debt are kept separate in the equity-value bridge.
Management/accounting	Dividends/FCF, buyback price discipline, incentives, dilution, related parties, abnormal items, and audit risks remain follow-up items.

Financial Audit

The audit base uses FY2021-FY2025 complete fiscal years. Financial currency is CNY, quote currency is CNY, and no FX translation is required. The same-currency 10-year sovereign yield used for valuation is CNY 1.74% as of 2026-07-10. ROIC is not used as a central conclusion when it cannot be reconstructed consistently from the common baseline.

The audit read-through is deliberately conservative. Five complete fiscal years are required for publication. If FCF drops below the normalized anchor, if working-capital swings prove non-repeatable, or if accounting and governance evidence weakens, the valuation multiple and signal should be reduced rather than defended with optimistic assumptions.

Shareholder Return

Dividends and buybacks are not added on top of fair value. They are used to judge whether management increases per-share intrinsic value while preserving FCF coverage.

Item	Discipline
Dividends	Dividend yield, payout ratio, and dividends/FCF must be checked from filings or official distribution records before they can support a higher score.
Buybacks	Buyback quality depends on net share-count change and repurchase price versus FV.
Incentives/dilution	Options, RSUs, convertibles, or other dilution must be quantified when material.
Capital allocation	Reinvestment or cash returns must support per-share value without weakening the cash-flow anchor.

Valuation

The valuation uses normalized FCF as the main anchor, applies a balance-sheet bridge, and then checks conservative, base, and optimistic scenarios. The optimistic case is a bounded sensitivity and cannot upgrade the signal by itself.

Scenario	Core assumption	Multiple discipline	Fair market value	FV/share	Current price/FV	Weight	Follow-up check
Conservative	normalized FCF 10.0 x 100m CNY, without relying on aggressive growth	g 0%-1%, 12x, evidence haircut	130.0 x 100m CNY	42.95CNY	2.08	30%	whether FCF below the conservative anchor is only short-term noise
Base	normalized FCF 13.4 x 100m CNY, maintaining the current quality tier	g 1%-3%, 15x, matched to a good/watch business tier	210.2 x 100m CNY	69.48CNY	1.29	50%	whether revenue and FCF continue the five-year trend
Optimistic	normalized FCF 16.1 x 100m CNY, with better operations and capital allocation	g 2%-5%, 17x, capped by the 20x rule	282.5 x 100m CNY	93.36CNY	0.96	20%	segment growth and shareholder returns require primary evidence

Cross-checks:

• FCF anchor: the base-case FV is 69.48 CNY; current price/base FV is 1.29.
• Downside protection: the conservative FV is 42.95 CNY; this is the first check before any buy signal.
• Reverse DCF: current price requires the FCF anchor and valuation multiple to hold together. Any miss in revenue, FCF, or primary evidence raises current price/FV.
• Balance sheet: cash, financial assets, debt, dilution, and off-balance-sheet claims are bridged to common-equity value with haircuts.

Buy And Tracking Discipline

Item	Conclusion
Current action	WATCHLIST: WATCHLIST is retained because current price/base FV is 1.29, leaving insufficient margin of safety or insufficient primary-evidence support for a buy signal.
Buy condition	A stronger signal requires current price/base FV below 0.70, continued support for the FCF anchor, and no deterioration in management/accounting evidence.
2x condition	A high-conviction 2x signal requires current price/base FV at or below 0.50 and evidence quality strong enough that downside protection is not merely optimistic.
Follow-up focus	FCF anchor, segment evidence, dividends/FCF, buyback price, incentive dilution, related parties, accounting quality, and regulatory or demand changes.

Risks To Track

Risk	Reading	Effect on valuation or signal
FCF quality	Watch the repeatability of the normalized FCF anchor.	Lower repeatable FCF reduces FV and can force a lower multiple.
Balance sheet	Keep cash, financial assets, debt, dilution, and claims separate.	Over-recognizing broad financial assets would overstate common-equity value.
Accounting/governance	Abnormal gains or losses, related parties, incentives, and audit matters remain constraints.	Weak evidence caps the signal even when headline FV looks attractive.
Shareholder return	Dividends and buybacks must be covered by FCF and done at sensible prices.	Poor capital allocation blocks an upgrade and can turn cheapness into a value trap.

Re-rating requires evidence, not just price movement: FCF staying more than 20% above the base anchor can lift FV, while FCF/net income below 0.60, weaker disclosures, deteriorating competition, regulation, or product economics should reduce the score or signal.

Research statement: this memo is for research only and is not personalized investment advice.

Data Sources

Use	Source	Date	URL
Current price, market capitalization, share count, and five-year financial baseline	Market and financial data platform used by the Chinese source memo	2026-07-11	Source file: 2026-07-11/stock-audit-300896.SZ-2026-07-11.md
Annual/interim reports, dividends, buybacks, governance, incentives, related parties, and risk disclosures	Official company and exchange disclosures named in the Chinese source memo	Latest available filings through this memo date	Source file: 2026-07-11/stock-audit-300896.SZ-2026-07-11.md
Risk-free rate and FX treatment	Sovereign-yield and FX sources named in the Chinese source memo	2026-07-11	See source memo